Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease

Wilson, J. Deanna; Lanzkron, Sophie; Pecker, Lydia H.; Bediako, Shawn M.; Han, Dingfen; Beach, Mary Catherine

doi:10.1080/10826084.2020.1797807

Cited by 6 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, this is lower than US general population data from around the same time, for example in 2015 the lifetime history of illicit drug use was 48.8%, with 44.0% reporting lifetime history of cannabis use 157 . Although not controlled for disease severity, higher measures of depressive symptoms, stress and lower QOL were associated with self‐report history of substance use 156 …”

Section: Substance Usementioning

confidence: 82%

“…An observational study of 258 patients with SCD aged 15 and older gathered self‐report history of illicit substance use including heroin, cocaine, amphetamines and cannabis. Nearly a quarter of participants reported lifetime history of substance use, primarily cannabis 156 . Notably, this is lower than US general population data from around the same time, for example in 2015 the lifetime history of illicit drug use was 48.8%, with 44.0% reporting lifetime history of cannabis use 157 .…”

Section: Substance Usementioning

confidence: 84%

“…157 Although not controlled for disease severity, higher measures of depressive symptoms, stress and lower QOL were associated with self-report history of substance use. 156 In the last 20 years cannabis use has increased in the general US population 158 a trend also observed in patients with SCD internationally. The prevalence of self-reported cannabis use increased from 2000 to 2004 in the Jamaica Sickle Cell Cohort Study (JSCCS).…”

Section: Su Bsta Nce Usementioning

confidence: 96%

See 2 more Smart Citations

Psychiatric comorbidities in adults with sickle cell disease: A narrative review

Mishkin

Prince²,

Leimbach

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryAlthough descriptions of quality of life and patient reports of mood in sickle cell disease (SCD) have become more common in the literature, less is known about psychiatric illness prevalence, presentation, and treatment, particularly for adults. We provide a narrative review of what is known about common and debilitating psychiatric conditions such as depression, anxiety, and cognitive impairment, specifically for adults with SCD. We discuss the limitations of the current evidence, make provisional recommendations, and identify opportunities for research and improved care.

show abstract

Section: Substance Usementioning

confidence: 82%

Section: Substance Usementioning

confidence: 84%

Section: Su Bsta Nce Usementioning

confidence: 96%

See 1 more Smart Citation

Psychiatric comorbidities in adults with sickle cell disease: A narrative review

Mishkin

Prince²,

Leimbach

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…In a preliminary study of 12 adolescents with mean age of 15 years, with 75% females and 83% of subjects on hydroxyurea, higher PainDETECT scores were significantly associated with lower PedsQL (indicator of HRQoL) scores [121]. Cannabis use in teenagers with SCD and cystic fibrosis is prevalent, although to a lower extent than their peers [120], which may be due to the perception of cannabis use associating with worse self-care, more stress, and more distress [113,114].…”

Section: Juvenile Use Of Cannabis In Scdmentioning

confidence: 99%

Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease

Argueta

Aich

Muqolli

et al. 2020

JCM

View full text Add to dashboard Cite

Pain in Sickle Cell Disease (SCD) is a major comorbidity and unique with acute pain due to recurrent and episodic vaso-occlusive crises as well as chronic pain, which can span an individual’s entire life. Opioids are the mainstay treatment for pain in SCD. Due to recent health crises raised by adverse effects including deaths from opioid use, pain management in SCD is adversely affected. Cannabis and its products are most widely used for pain in multiple conditions and also by patients with SCD on their own. With the availability of “Medical Cannabis” and approval to use cannabis as medicine across majority of States in the United States as well as over-the-counter preparations, cannabis products are being used increasingly for SCD. The reliability of many of these products remains questionable, which poses a major health risk to the vulnerable individuals seeking pain relief. Therefore, this review provides up to date insights into available categories of cannabis-based treatment strategies, their mechanism of action and pre-clinical and clinical outcomes in SCD. It provides evidence for the benefits and risks of cannabis use in SCD and cautions about the unreliable and unvalidated products that may be adulterated with life-threatening non-cannabis compounds.

show abstract

“…[4] In addition to the medical syndromes experienced by individuals with SCA, there is an interplay of psychosocial challenges, including mental disorders, pain crises, sleep disorders, interpersonal relationships, substance abuse, stigma, and workplace discrimination, as suggested by literature. [5][6][7][8][9][10] However, a wider array of psychosocial challenges impacting the patients, their family and peers, and ignored can affect overall response to management, has been underrepresented in literature. [11] As a result, SCA patients have reported negative experiences due to practitioners ignoring or undermining the effect of these less overt challenges.…”

Section: Introductionmentioning

confidence: 99%

Psychosocial challenges of persons with sickle cell anemia: A narrative review

Essien,

Winter-Eteng,

Onukogu

et al. 2023

Medicine

View full text Add to dashboard Cite

Sickle cell anemia (SCA) is a severe form of sickle cell disease that primarily affects black populations and individuals in tropical countries. This condition causes significant morbidity and mortality and leads to a range of psychosocial challenges. A preliminary search was conducted on Ovid Medline and public databases with a combination of Medical Subject Headings keywords, resulting in 368 articles. The articles were screened based on the selection criteria in a nonsystematic method by 3 researchers, and a narrative synthesis was done to analyze extracted data from selected peer-reviewed article. Mental disorders, sleep disturbances, interpersonal relationship challenges, stigmatization, and workplace discrimination were identified as significant contributors to the psychosocial distress experienced by individuals with SCA and their families. Depression and anxiety were prevalent among individuals with SCA, leading to poor treatment adherence, increased pain, and disruptions in various aspects of life. Sleep disturbances, including sleep-disordered breathing and sleepwalking, were also identified as significant contributors to poor sleep quality in SCA patients. Families of individuals with SCA also face challenges, including psychological stress, financial strain, and social disruption. Stigmatization is common, leading to misconceptions and discrimination. Workplace discrimination is prevalent, with a high unemployment rate among adult SCA patients. Comprehensive care is crucial to address these psychosocial issues. Early identification and intervention, comprehensive support programs, patient and family education, enhanced pain management strategies, and integration of mental health into clinical care are recommended. School-based support, research and advocacy, and community support groups are also important. By addressing these challenges through comprehensive care and support, healthcare professionals, policymakers, and society can reduce psychosocial distress and improve the lives of individuals with SCA.

show abstract

Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease

Cited by 6 publications

References 60 publications

Psychiatric comorbidities in adults with sickle cell disease: A narrative review

Psychiatric comorbidities in adults with sickle cell disease: A narrative review

Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease

Psychosocial challenges of persons with sickle cell anemia: A narrative review

Contact Info

Product

Resources

About